MA52486A - Pyridazinones utilisés en tant qu'inhibiteurs de parp7 - Google Patents

Pyridazinones utilisés en tant qu'inhibiteurs de parp7

Info

Publication number
MA52486A
MA52486A MA052486A MA52486A MA52486A MA 52486 A MA52486 A MA 52486A MA 052486 A MA052486 A MA 052486A MA 52486 A MA52486 A MA 52486A MA 52486 A MA52486 A MA 52486A
Authority
MA
Morocco
Prior art keywords
pyridazinones
parp7
inhibitors
parp7 inhibitors
pyridazinones used
Prior art date
Application number
MA052486A
Other languages
English (en)
Other versions
MA52486B1 (fr
Inventor
Kevin Wayne Kuntz
Laurie B Schenkel
Kerren Kalai Swinger
Melissa Marie Vasbinder
Original Assignee
Ribon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribon Therapeutics Inc filed Critical Ribon Therapeutics Inc
Publication of MA52486A publication Critical patent/MA52486A/fr
Publication of MA52486B1 publication Critical patent/MA52486B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA52486A 2018-04-30 2019-04-29 Pyridazinones utilisés en tant qu'inhibiteurs de parp7 MA52486B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862664544P 2018-04-30 2018-04-30
PCT/US2019/029582 WO2019212937A1 (fr) 2018-04-30 2019-04-29 Pyridazinones utilisés en tant qu'inhibiteurs de parp7

Publications (2)

Publication Number Publication Date
MA52486A true MA52486A (fr) 2021-03-10
MA52486B1 MA52486B1 (fr) 2023-04-28

Family

ID=66476851

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52486A MA52486B1 (fr) 2018-04-30 2019-04-29 Pyridazinones utilisés en tant qu'inhibiteurs de parp7

Country Status (36)

Country Link
US (6) US10550105B2 (fr)
EP (2) EP3788040B1 (fr)
JP (2) JP6942896B2 (fr)
KR (1) KR102862474B1 (fr)
CN (2) CN120987912A (fr)
AR (1) AR121419A1 (fr)
AU (2) AU2019262927B2 (fr)
BR (1) BR112020022006A2 (fr)
CA (1) CA3098585A1 (fr)
CL (1) CL2020002821A1 (fr)
CO (1) CO2020013599A2 (fr)
CR (1) CR20200518A (fr)
CY (1) CY1126132T1 (fr)
DK (1) DK3788040T3 (fr)
EA (1) EA202092590A1 (fr)
EC (1) ECSP20069404A (fr)
ES (1) ES2949538T3 (fr)
FI (1) FI3788040T3 (fr)
HR (1) HRP20230458T1 (fr)
HU (1) HUE062096T2 (fr)
IL (2) IL308983B2 (fr)
LT (1) LT3788040T (fr)
MA (1) MA52486B1 (fr)
MD (1) MD3788040T2 (fr)
MX (2) MX2020011465A (fr)
PE (1) PE20211382A1 (fr)
PH (1) PH12020551760A1 (fr)
PL (1) PL3788040T3 (fr)
PT (1) PT3788040T (fr)
RS (1) RS64283B1 (fr)
SG (1) SG11202010183XA (fr)
SI (1) SI3788040T1 (fr)
SM (1) SMT202300172T1 (fr)
TW (2) TWI877697B (fr)
WO (1) WO2019212937A1 (fr)
ZA (1) ZA202006549B (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3788040T1 (sl) 2018-04-30 2023-07-31 Ribon Therapeutics Inc. Piridazinoni kot zaviralci parp7
US11293927B2 (en) 2018-04-30 2022-04-05 Ribon Therapeutics, Inc. Screening methods for PARP modulators
WO2019241131A1 (fr) 2018-06-11 2019-12-19 Pipeline Therapeutics, Inc. Antagonistes des récepteurs muscariniques de l'acétylcholine m1
US12054487B2 (en) 2018-09-04 2024-08-06 Contineum Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
IL286481B2 (en) * 2019-03-20 2025-12-01 Goldfinch Bio Inc Pyridazinones and methods of use thereof
US12371421B2 (en) 2019-04-29 2025-07-29 Ribon Therapeutics, Inc. Solid forms of a PARP7 inhibitor
IL326597A (en) * 2019-10-07 2026-04-01 Contineum Therapeutics Inc Muscarinic M1 acetylcholine receptor antagonists
MX2022005216A (es) * 2019-10-30 2022-06-02 Ribon Therapeutics Inc Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7).
US20240190844A1 (en) * 2019-10-30 2024-06-13 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
TW202206422A (zh) * 2020-04-23 2022-02-16 美商普雷辛肯公司 用於ｃｄ７３調節之化合物及方法及其適應症
WO2021248231A1 (fr) * 2020-06-09 2021-12-16 Relive Therapeutics Inc. Composés comprenant un noyau à trois cycles en tant que bloqueurs de pd-1/pd-l1
IL299623A (en) * 2020-07-03 2023-03-01 Wuhan Ll Science & Technology Development Co Ltd Heterocyclic compound and its use
WO2022111700A1 (fr) * 2020-11-27 2022-06-02 成都百裕制药股份有限公司 Dérivés de pyridazinone et leur utilisation en médecine
JP7623826B2 (ja) * 2020-12-18 2025-01-29 株式会社 資生堂 Ｔｉｐａｒｐ産生促進剤
WO2022156708A1 (fr) * 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Inhibiteur d'enzyme parp7
CN116724044B (zh) * 2021-02-03 2025-10-31 上海湃隆生物科技有限公司 三并杂环类化合物、其制备方法及其应用
EP4289846A4 (fr) * 2021-02-07 2025-01-22 Wuhan LL Science and Technology Development Co., Ltd. Composé hétérocyclique, et son intermédiaire, leur procédé de préparation et leur utilisation
EP4291560A4 (fr) * 2021-02-09 2025-01-15 Jacobio Pharmaceuticals Co., Ltd. Dérivés tricycliques utiles en tant qu'inhibiteurs de parp7
TW202245777A (zh) * 2021-02-16 2022-12-01 美商律幫治療股份有限公司 Parp7抑制劑之給藥方案
CN115028648B (zh) * 2021-03-03 2024-08-30 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
WO2022188889A1 (fr) * 2021-03-12 2022-09-15 杭州英创医药科技有限公司 Composé utile en tant qu'inhibiteur de parp7
WO2022194122A1 (fr) * 2021-03-16 2022-09-22 上海翰森生物医药科技有限公司 Composé hétérocyclique polycyclique contenant de l'azote, son procédé de préparation et son utilisation
GB202114315D0 (en) * 2021-10-06 2021-11-17 Duke Street Bio Ltd Pharmaceutical compound
US20240217968A1 (en) * 2021-03-31 2024-07-04 Duke Street Bio Limited Pharmaceutical compound
CN117083274A (zh) * 2021-04-23 2023-11-17 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
KR20240012534A (ko) * 2021-05-21 2024-01-29 청두 바이위 파머수티컬 씨오., 엘티디 피페라진 유도체 및 이의 의학적 용도
CN117396485B (zh) * 2021-05-25 2026-01-30 轩竹生物科技股份有限公司 Parp7抑制剂
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药（上海）有限公司 作为parp7抑制剂的哒嗪酮类化合物
CN117751108A (zh) * 2021-07-21 2024-03-22 南京明德新药研发有限公司 哒嗪酮类化合物
WO2023001296A1 (fr) * 2021-07-23 2023-01-26 武汉人福创新药物研发中心有限公司 Composé de pyridazinone utile en tant qu'inhibiteur de parp7
WO2023011629A1 (fr) * 2021-08-06 2023-02-09 成都百裕制药股份有限公司 Dérivé de pyrrolidone et son utilisation en médecine
CN117377665B (zh) * 2021-08-16 2026-04-21 重庆华森英诺生物科技有限公司 Parp7抑制剂及其应用
US20240343727A1 (en) * 2021-08-17 2024-10-17 InventisBio Co., Ltd. Pyridazinone or pyridinone compounds, preparation methods and uses thereof
AU2022375782B2 (en) 2021-10-28 2026-02-26 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CN115745971B (zh) * 2021-12-20 2024-07-30 北京华森英诺生物科技有限公司 Parp7抑制剂及其应用
CN116375688B (zh) * 2021-12-23 2025-04-11 中国药科大学 哒嗪酮类化合物及其制备方法、药物组合物和应用
CN116444497B (zh) * 2022-01-14 2025-06-24 如东凌达生物医药科技有限公司 一类哒嗪酮类化合物、制备及其应用
CN116535395B (zh) * 2022-01-26 2024-07-09 中国药科大学 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用
WO2023143236A1 (fr) * 2022-01-26 2023-08-03 中国药科大学 Composé de 2h-indazole-7-formamide, procédé de préparation, composition pharmaceutique, et application
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
EP4338737A4 (fr) * 2022-04-01 2024-11-06 Novostar Pharmaceuticals, Ltd. Inhibiteur de parp7 et son utilisation
TW202346294A (zh) * 2022-04-21 2023-12-01 大陸商四川海思科製藥有限公司 吡嗪酮衍生物及其在醫藥上的應用
AU2023321458B2 (en) * 2022-08-09 2026-05-07 Kangbaida (Sichuan) Biotechnology Co., Ltd. Use of piperazine compound in combination with radiotherapy for treatment of tumor
CN117586263B (zh) * 2022-08-09 2026-04-10 康百达（四川）生物医药科技有限公司 哌嗪衍生物及其在医药上的应用
CN119546614A (zh) * 2022-08-09 2025-02-28 康百达（四川）生物医药科技有限公司 哌嗪类化合物和pd-1抑制剂或pd-l1抑制剂的组合物以及其治疗肿瘤的用途
AR130230A1 (es) * 2022-08-17 2024-11-20 Jacobio Pharmaceuticals Co Ltd Formas sólidas del compuesto i o sales del mismo
GB202213819D0 (en) 2022-09-22 2022-11-09 Duke Street Bio Ltd Pharmaceutical compound
CN115490671B (zh) * 2022-10-21 2024-05-14 水木未来(北京)科技有限公司 Parp7抑制剂及其制备方法
CN117551080A (zh) * 2022-11-11 2024-02-13 杭州师范大学 一种靶向降解parp7的protac化合物及其制备方法与应用
JP2025536416A (ja) * 2022-11-14 2025-11-05 康百達（四川）生物医薬科技有限公司 置換ピペラジン誘導体の結晶およびその調製方法
GB202217888D0 (en) 2022-11-29 2023-01-11 Duke Street Bio Ltd Pharmaceutical compound
WO2024146631A1 (fr) * 2023-01-06 2024-07-11 齐鲁制药有限公司 Procédé de préparation d'inhibiteur de parp7
WO2024149234A1 (fr) * 2023-01-10 2024-07-18 Angel Pharmaceutical Co., Ltd. Inhibiteurs de parp7 et leurs utilisations
WO2024149231A1 (fr) * 2023-01-10 2024-07-18 Angel Pharmaceutical Co., Ltd. Inhibiteurs de parp7 et leurs utilisations
CN118388414A (zh) * 2023-01-17 2024-07-26 中国药科大学 哒嗪酮类化合物及其制备方法、药物组合物和应用
WO2025036478A1 (fr) * 2023-08-17 2025-02-20 康百达（四川）生物医药科技有限公司 Préparation pharmaceutique de dérivé de pipérazine, son procédé de préparation et son utilisation
TWI910796B (zh) * 2023-08-29 2026-01-01 大陸商康百達（四川）生物醫藥科技有限公司 一種呱嗪衍生物的製備方法及其中間體
WO2025087383A1 (fr) * 2023-10-26 2025-05-01 深圳众格生物科技有限公司 Composé agissant en tant qu'inhibiteur de parp7
WO2025103341A1 (fr) * 2023-11-13 2025-05-22 康百达（四川）生物医药科技有限公司 Combinaison pharmaceutique d'un médicament combiné à un inhibiteur de parp7, et son utilisation dans le traitement de tumeurs
CN117342983B (zh) * 2023-12-05 2024-02-06 康羽生命科学技术(苏州)有限公司 过乙酰化GalNAc-L96合成方法
WO2025209574A1 (fr) * 2024-04-03 2025-10-09 康百达（四川）生物医药科技有限公司 Inhibiteur de parp7 pour la prévention ou le traitement de tumeurs

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE317122T1 (de) 1997-09-05 2006-02-15 Matsushita Electric Industrial Co Ltd Fluoreszierende polarisation
WO2002082082A2 (fr) 2001-04-09 2002-10-17 Boehringer Ingelheim Pharmaceuticals, Inc. Analyse par polarisation de fluorescence
HU227237B1 (en) * 2001-09-27 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
GB0301628D0 (en) 2002-09-19 2003-02-26 Aventis Pharma Inc Method for assaying compounds that decrease the activity of poly (ADP-ribose) - polymerase (PARP)
WO2006003150A1 (fr) * 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Derives de 2-alkyl quinazolinone substitues en tant qu'inhibiteurs de parp
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
MX2009000884A (es) 2006-07-25 2009-06-05 Cephalon Inc Derivados de piridizinona.
WO2009063244A1 (fr) 2007-11-15 2009-05-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Derivés de pyridazinone inhibiteurs de la parp
JP5492183B2 (ja) * 2008-03-27 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐおよびチューブリン重合阻害剤としてのテトラヒドロフェナントリジノンおよびテトラヒドロシクロペンタキノリノン
NZ598262A (en) * 2009-08-17 2014-05-30 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
CN103570725B (zh) * 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
WO2014143241A1 (fr) * 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de la kinase atr
WO2016116602A1 (fr) * 2015-01-23 2016-07-28 Astrazeneca Ab Traitement du cancer
CN106749261A (zh) * 2015-11-23 2017-05-31 中国科学院上海药物研究所 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
AU2018334290A1 (en) * 2017-09-18 2020-04-02 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
GB201717080D0 (en) 2017-10-18 2017-11-29 Syngenta Participations Ag Chemical process
US11293927B2 (en) 2018-04-30 2022-04-05 Ribon Therapeutics, Inc. Screening methods for PARP modulators
SI3788040T1 (sl) * 2018-04-30 2023-07-31 Ribon Therapeutics Inc. Piridazinoni kot zaviralci parp7
US12371421B2 (en) 2019-04-29 2025-07-29 Ribon Therapeutics, Inc. Solid forms of a PARP7 inhibitor
MX2022005216A (es) 2019-10-30 2022-06-02 Ribon Therapeutics Inc Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7).
US20240190844A1 (en) 2019-10-30 2024-06-13 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors

Also Published As

Publication number Publication date
IL308983B1 (en) 2025-06-01
HUE062096T2 (hu) 2023-09-28
IL278116A (en) 2020-11-30
EP4234551A2 (fr) 2023-08-30
ES2949538T3 (es) 2023-09-29
JP2022017221A (ja) 2022-01-25
WO2019212937A1 (fr) 2019-11-07
JP7518049B2 (ja) 2024-07-17
MX2023005804A (es) 2023-05-29
AU2024200566A1 (en) 2024-02-15
US11566020B1 (en) 2023-01-31
TWI811353B (zh) 2023-08-11
EP4234551A3 (fr) 2023-10-11
JP6942896B2 (ja) 2021-09-29
SI3788040T1 (sl) 2023-07-31
US20200123134A1 (en) 2020-04-23
IL308983B2 (en) 2025-10-01
TW202344505A (zh) 2023-11-16
PE20211382A1 (es) 2021-07-27
DK3788040T3 (da) 2023-05-08
CY1126132T1 (el) 2023-11-15
CO2020013599A2 (es) 2020-12-21
CN120987912A (zh) 2025-11-21
CN112424188B (zh) 2025-06-27
PH12020551760A1 (en) 2021-06-28
AU2024200566B2 (en) 2026-03-05
US10870641B2 (en) 2020-12-22
TWI877697B (zh) 2025-03-21
KR20210014108A (ko) 2021-02-08
US20230192664A1 (en) 2023-06-22
CL2020002821A1 (es) 2021-02-19
SG11202010183XA (en) 2020-11-27
PT3788040T (pt) 2023-07-12
MX2020011465A (es) 2020-12-07
SMT202300172T1 (it) 2023-09-06
KR102862474B1 (ko) 2025-09-24
AR121419A1 (es) 2022-06-08
CA3098585A1 (fr) 2019-11-07
FI3788040T3 (fi) 2023-06-13
IL278116B1 (en) 2023-12-01
EP3788040A1 (fr) 2021-03-10
AU2019262927B2 (en) 2023-11-02
IL308983A (en) 2024-01-01
EA202092590A1 (ru) 2021-04-08
MA52486B1 (fr) 2023-04-28
CN112424188A (zh) 2021-02-26
US20250034120A1 (en) 2025-01-30
MD3788040T2 (ro) 2023-10-31
LT3788040T (lt) 2023-06-26
US20190330194A1 (en) 2019-10-31
US10550105B2 (en) 2020-02-04
BR112020022006A2 (pt) 2021-01-26
JP2021523104A (ja) 2021-09-02
TW202014416A (zh) 2020-04-16
US11014913B2 (en) 2021-05-25
EP3788040B1 (fr) 2023-04-12
CR20200518A (es) 2021-03-22
ZA202006549B (en) 2025-06-25
AU2019262927A1 (en) 2020-11-12
HRP20230458T1 (hr) 2023-07-21
IL278116B2 (en) 2024-04-01
ECSP20069404A (es) 2021-01-29
US20210024502A1 (en) 2021-01-28
PL3788040T3 (pl) 2023-08-07
RS64283B1 (sr) 2023-07-31

Similar Documents

Publication Publication Date Title
MA54076A (fr) 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu&#39;inhibiteurs de nav1.8
EP3873468A4 (fr) 2-amino-n-phényl-nicotinamides utilisés en tant qu&#39;inhibiteurs de nav1.8
MA49566A (fr) Carboxamides utilisés en tant qu&#39;inhibiteurs des canaux sodiques
MA43169A (fr) Composés hétérocycliques utilisés en tant qu&#39;inhibiteurs de pi3k-gamma
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu&#39;inhibiteurs de kinase
MA49888A (fr) Composés macrocycliques utilisés en tant qu&#39;inhibiteurs de kinase ros1
MA47013A (fr) Composés benzolactames utilisés en tant qu&#39;inhibiteurs de protéine kinase
MA51438A (fr) Composés hétérocycliques utilisés en tant qu&#39;inhibiteurs de lsd1
MA51616A (fr) Inhibiteurs d&#39;adn-pk
MA48994A (fr) Isoquinoléines utilisées en tant qu&#39;inhibiteurs de hpk1
MA51610A (fr) Dérivés d&#39;imidazole fusionnés utilisés en tant qu&#39;inhibiteurs d&#39;il-17
EP3768661A4 (fr) Composés deutérés utilisés en tant qu&#39;inhibiteurs de rock
EP3906029A4 (fr) Inhibiteurs de l&#39;interaction ménine-mll
MA49374A (fr) Composés hétéroaromatiques utilisés en tant qu&#39;inhibiteurs de vanine
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu&#39;inhibiteurs de parp
MA43862A (fr) Spiroheptane salicylamides et composés associés en tant qu&#39; inhibiteurs de rock
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu&#39;inhibiteurs de fgfr4
MA48803A (fr) Cycles 6-5 fusionnés utilisés en tant qu&#39;inhibiteurs de c5a
MA51429A (fr) Dérivés amino-fluoropipéridines utilisés en tant qu&#39;inhibiteur de kinase
EP3733673A4 (fr) Dérivés d&#39;oxy-fluoropipéridine utilisés en tant qu&#39;inhibiteur de kinase
MA45377A (fr) Composés hétérocycliques en tant qu&#39;agents antibacteriens
MA42919A (fr) Composés bicycliques utilisés en tant qu&#39;inhibiteurs d&#39;atx
MA45375A (fr) Composés hétérocycliques utilisés en tant qu&#39;agents antibacteriens
MA42918A (fr) Composés bicycliques utilisés en tant qu&#39;inhibiteurs d&#39;atx
MA54567A (fr) Pyridine et composés de pyridimine en tant qu&#39;inhibiteurs de pi3k-gamma